Lung cancer, the leading cause of cancer death, is usually diagnosed at a late stage when the survival rate is extremely low, but a new study published in Proceedings of the National Academy of Sciences provides proof-of-concept for the ability of a drop of blood to reveal lung cancer in asymptomatic patients, paving the way for early-stage lung cancer screening which may dramatically improve survival rates.
Early-stage lung cancer is mostly asymptomatic, and low-dose spiral CT imaging, the current method for detecting early lung cancer lesions, isn’t feasible as a widespread screening test for the general population because of high cost and the radiation hazard of repeated screenings.
“Our study demonstrates the potential for developing a sensitive screening tool for the early detection of lung cancer,” said Leo Cheng, Harvard Medical School associate professor in radiology and associate biophysicist in pathology and radiology at Massachusetts General Hospital.
“The predictive model we constructed can identify which people may be harboring lung cancer. Individuals with suspicious findings would then be referred for further evaluation by imaging tests, such as low-dose CT, for a definitive diagnosis,” Cheng said.
The study was co-led by Cheng, researchers at the Athinsula A. Martinos Center for Biomedical Imaging, and David Christiani, HMS professor of medicine and a pulmonary and critical care physician at Mass General.
Cheng, Christiani, and their co-investigators built a lung-cancer predictive model based on metabolomics profiles in blood.
Metabolomics analyzes cellular metabolite flows to decipher healthy and pathological states by studying the metabolome—the dynamic biochemical suite found in all cells, fluids, and tissues of the body.
The presence of lung cancer, with its altered physiology and pathology, can cause changes in the blood metabolites produced or consumed by cancer cells in the lungs.
The researchers measured metabolomics profiles in blood using high-resolution magnetic resonance spectroscopy, a tool that can examine an array of compounds within living cells by measuring the collective reactions of metabolites.
The investigators screened tens of thousands of blood specimens stored in Mass General’s and other biobanks and found 25 patients with non-small cell lung cancer (NSCLC) with stored blood specimens obtained at the time of their diagnosis and at least six months prior to their diagnosis. They matched these patients with 25 healthy individuals.
The researchers first trained their statistical model to recognize lung cancer by measuring metabolomic profile values in blood samples obtained from patients at the time of their diagnosis and comparing them to blood samples from the healthy people.
They then validated their model using blood samples from the same patients obtained prior to their lung cancer diagnosis. Here the predictive model yielded values between the healthy people and the patients at the time of their diagnosis.
“This was very encouraging, because screening for early disease should detect changes in blood metabolomic profiles that are intermediate between healthy and disease states,” said Cheng.
The investigators then tested their model with a different group of 54 patients with NSCLC using blood samples obtained before their cancer diagnosis, which confirmed that the model’s predictions were accurate.
Values from the predictive model measured from prior-to-diagnosis blood samples could also predict five-year survival for patients, which may be useful in guiding clinical strategies and treatment decisions.
A previous study by the investigators showed the potential for magnetic resonance spectroscopy-based metabolomics to differentiate cancer types and stages of diseases.
Larger studies are needed to validate the use of blood metabolomics models as NSCLC early screening tools in clinical practice.
Next, the researchers said they will analyze metabolomic profiles of lung cancer’s clinical characteristics to understand the entire metabolic spectrum of the disease, which may be useful in choosing targeted therapies.
They have also measured metabolomics profiles of more than 400 patients with prostate cancer to create a model that will distinguish between indolent cancer, which needs to be monitored, and more aggressive cancer that requires immediate treatment.
The investigators also plan to use the same technology to screen for Alzheimer’s disease using blood samples and cerebrospinal fluid.
The National Cancer Institute funded this study.
Adapted from a Mass General news release.